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a b s t r a c t 
The treatment of patients with acquired hemophilia is challenging due to life-threatening hemorrhages, 
delayed response, and adverse effects to immunosuppressive agents. Even though immunoadsorption (IA) 
rapidly removes autoantibodies against factor VIII, this intervention’s effectiveness is still a matter of 
debate. We aimed to study important outcomes of IA as adjunctive treatment in patients with acquired 
hemophilia. We performed comprehensive literature searches in MEDLINE and EMBASE databases. Clinical 
and laboratory data of all patients treated in our institution were additionally included. Literature search- 
ing yielded 498 records, of which 10 studies describing 106 patients were finally included. The number of 
patients varied from 1 to 65, and patients’ ages ranged between 14 and 89. Treatment criteria in most pa- 
tients were (1) failed response to immunosuppressive treatment alone, and/or (2) uncontrollable bleeding 
episodes, and/or (3) high inhibitor titer. Methodological quality was moderate. The number of IA sessions 
varied from 1 to 24. Within our institution, 12 patients have been treated since 2002; median age was 
76 years (range 34-86); median titer of factor VIII inhibitor was 20 Bethesda units (range 3-214). Pooled 
estimates, modeling a random-effect binominal distribution incorporating the Freeman-Tukey double arc- 
sine transformation, were 86% in case of factor VIII recovery (95% confidence interval 76%-94%), 95% for 
reduction of factor VIII inhibitor (83%, 100%), and 7% in case of death (0%, 18%). Our data suggest that 
IA might be a beneficial adjunctive treatment in patients with high-risk acquired hemophilia, but future 
studies shall confirm this observation. 
© 2021 The Authors. Published by Elsevier Inc. 
























Treatment of patients with acquired hemophilia is challenging.
Often, patients present with large ecchymosis, extensive muscle
hemorrhages, gastrointestinal bleeding, or even intracerebral hem-
orrhage [1-3] . The mortality is high because of bleeding compli-
cations and treatment complications such as infection [4 , 5] . The
pathogenesis of acquired hemophilia is heterogeneous. The most
common associated conditions are malignancy [6 , 7] , autoimmune
disorder [8-11] , drug-induced [12 , 13] , or postpartum status [14 , 15] .
On multivariate analysis, factors that predict improved overall
survival are the achievement of complete remission, age below∗ Correspondence to: Michael Nagler, MD, PhD, MSc, University Institute of Clini- 
cal Chemistry, Inselspital University Hospital, 3010 Bern, Switzerland. 
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been described by the EACH2 registry of 501 patients [16] . The
cohort comprised 266 men (53.1%) and 235 women (46.9%). The
median age at diagnosis was 73.9 years, demonstrating a prepon-
derance of older patients but the data revealed also a second small
population of younger female patients ( n = 42; 8.4%) with a me-
dian age of 33.9 years who presented with peripartum acquired
hemophilia (8 antepartum and 34 postpartum). Whereas the whole
EACH2 cohort showed upon treatment a CR of 73% and a prelimi-
nary survival rate of 68% at final follow up, 36 of 42 women were
in CR (86%), and 40 of 40 (100%) alive at final follow up [17] . This
excellent survival reflects the younger age and better overall health
of the female subgroup and has been described by other retrospec-
tive studies and reviews. 
Physicians are confronted with a variety of drugs to stop the
bleeding and eradicate the inhibitor against factor VIII (FVIII)
[5 , 18-20] . However, results from randomized controlled trials tonder the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) 
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inform physicians regarding treatment decisions are not available.
Stopping the bleeding is the first treatment objective, which is
pursued using recombinant activated factor VII (rFVIIa), porcine
VIII, activated prothrombin complex concentrate, or even high-dose
human FVIII [4 , 5 , 18 , 20 , 21] . To prevent additional bleeding, some
patients have been treated with emicizumab, a bispecific FVIIIa
mimetic antibody, with interesting responses [22] . Even though
it is not yet approved for acquired hemophilia and clinical tri-
als are missing, it has possible hemostatic prophylactic effectiv-
ity with weekly or bi-weekly subcutaneous injection-application,
can be done in an outpatient setting, and is bridging the time un-
til immunosuppression is effective. To eradicate inhibitors against
FVIII, a combined immunosuppressive treatment can be applied.
Often, a combination of corticosteroids and cyclophosphamide is
given [18 , 23] . However, response to treatment might take several
weeks or even months and the treatment is not successful in a
relevant number of patients [16 , 24-26] . Other immunosuppressive
regimens include azathioprine, mycophenolate mofetil, and borte-
zomib [27 , 28] . Because of the low rate of adverse events, Ritux-
imab has recently gained increasing acceptance in combination
with steroids, used in the first line or the second line after no
response to cyclophosphamide and steroid treatment, but these
regimes have not yet been studied in controlled trials [17 , 29-31] . 
immunoadsorption (IA) is suggested to rapidly eradicate au-
toantibodies against FVIII by removing circulating immunoglob-
ulins [32] . Patient plasma is separated from whole blood using
a plasma separation device and it is passed through columns
containing absorbent ligands [33-35] . Several adsorbent ligands
are used: (1) re-usable columns comprised of Staphylococcus
aureus protein A and bound to sepharose matrix (protein A
sepharose) [36-38] , (2) re-usable columns with antihuman IgG
sheep bound to sepharose matrix (Therasorb-Ig) [36-38] , (3) dis-
posable tryptophan-based columns (Immusorba TR-350) [39-41] ,
and (4) a synthetic peptide GAM bound to sepharose matrix
(Globaffin) [42 , 43] . With most columns, IgG immunoglobulins are
selectively removed [36] and the inhibitor titers of the autoanti-
bodies are lowered significantly within few sessions [44] . How-
ever, publications describing the clinical effectiveness of this ap-
proach are scarce and scattered in the literature. Comparable to
other rare diseases, no randomized controlled trials have been con-
ducted. Thus, no conclusion or recommendation as to whether or
not IA should be implemented in treatment regimens for acquired
hemophilia has been made to date [4 , 18 , 23 , 36 , 45-47] . 
Aim 
The aim of the present investigation was to systematically
search and retrieve available clinical and laboratory data from
studies describing the use of IA for the treatment of acquired
hemophilia, to report on patients treated on our own institution in
this way, and to summarize all data using meta-analytic methods. 
Methods 
Study Design and Setting 
In a retrospective cohort study, we systematically searched and
retrieved data from all patients with acquired hemophilia treated
at our institution between 2002 and May 2019. Inselspital Bern is
the only tertiary hospital in the Greater Bern Area covering more
than 1.5 million inhabitants. Due to the retrospective design and
absence of general informed consent of patients attending the hos-
pital before 2016, not all patients had provided informed consent
– the local ethics committee waived this need. The local ethics
committee approved the protocol (Ethikkommission Bern #2019-Please cite this article as: M. Esteves Pereira, C. Bocksrucker, J.A. Kreme
Hemophilia: New Observational Data, Systematic Review, and Meta-A
tmrv.2021.01.001 00478) and we conducted the study in accordance with the Decla-
ration of Helsinki. 
Inclusion Criteria and Identification of Patients 
Patients were identified from the patient documentation within
the apheresis unit. Inclusion criteria were an established diagnosis
of acquired hemophilia with a FVIII activity below 5 IU/dL and an
inhibitor titer > 1 BU/mL. Predefined clinical data including year of
diagnosis, age at admission, sex, bleeding presentation, concomi-
tant disorders, aPTT, FVIII activity and inhibitor titer were retrieved
in duplicate (MP, MN) from electronic patient documentation. In
addition, FVIII recovery, reduction of the inhibitor titer, bleeding
events and deaths were recorded at predefined follow-up time
points: 30 days, 3 months and 12 months. A specifically designed
data extraction form was used, and the accuracy was checked by
a second investigator (MN). Discrepancies were resolved by discus-
sion. 
Systematic Review: Study Identification, Eligibility, and Data 
Extraction 
A search strategy for MEDLINE and EMBASE was developed us-
ing the Ovid interface and refined using keywords from references
found in a pilot search and after manual review of reference lists
(Supplementary Material). No restrictions with regard to language
or publication date were applied. The last search run was per-
formed on October 29, 2019 and obtained records were screened
by 2 investigators in parallel (MN, MP). The titles and abstracts of
all hits were assessed for eligibility. The following inclusion crite-
ria were applied: (1) acquired hemophilia patients with FVIII lev-
els below 20%, and an inhibitor titer ≥1, (2) patients that have
had at least 1 session of IA in addition to standard treatment,
(3) laboratory outcomes reported (FVIII recovery and/or course of
inhibitor titer), and (4) reporting of clinical outcomes (bleeding
events and/or mortality). Studies were excluded if (1) only patients
with hereditary hemophilia were described, (2) plasma exchange
was conducted, (3) no clinical outcomes were reported, or (4) no
laboratory outcomes were presented. The most complete publica-
tion was selected where multiple publications describing the same
cohort were found. Full-text articles were assessed by 2 investi-
gators. Studies selected for inclusion were reviewed in duplicate
and the following data were extracted: author, year of publication,
number of patients, age range, sex, aPTT, FVIII, inhibitor titer, co-
treatment and observation period. The treatment protocols, includ-
ing the absorbing agent, the number of IA sessions and the co-
treatment(s) were extracted, as well as FVIII-recovery, reduction
of the inhibitor titer, remission status and death. The systematic
review protocol used here was submitted to the PROSPERO inter-
national prospective register of systematic reviews and the results
have been reported according to the PRISMA guideline. 
Assessment of Methodological Quality 
For assessment of methodological quality, we used the
Newcastle-Ottawa Scale (NOS; http://www.ohri.ca/programs/
clinical _ epidemiology/oxford.asp ). The NOS is an established tool
to assess the methodological quality of nonrandomized studies
including case-control and cohort studies [48] . The following
items were assessed: (1) representative patients, (2) control group
selected, (3) patients treated, (4) end points absent at the start of
treatment, (5) control group comparable, (6) determination of end
points, (7) interval of follow-up, and (8) complete follow-up. r Hovinga et al., Immunoadsorption for the Treatment of Acquired 
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Table 1 
Characteristics of patients receiving an IA treatment for acquired hemophilia at our institution, Inselspital, Bern University Hospital. 
Patient number Year of diagnosis Age Sex Type of bleeding Concomitant disorders aPTT FVIIl activity Inhibitor titer 
Years Seconds IU/dL BU/mL 
1 2002 77 Female GI bleeding Osteoporosis, COPD 52 < 1 3 
2 2002 75 Female GI bleeding Sjogren syndrome 55 < 1 18 
3 2003 53 Male Extensive bruising Chronic hepatitis C 57 < 1 16 
4 2004 34 Female Extensive bruising nr 130 3 > 200 
5 2006 80 Male Extensive bruising CHD, hypertension, renal impairment 65 < 1 13 
6 2010 70 Female Extensive bruising, GI bleeding Sepsis, diabetes type 2 68 3.5 15 
7 2012 77 Male Bleeding after tooth extraction Granulomatosis with polyangiitis, 
atrial fibrillation, renal impairment 
108 < 1 32 
8 2013 81 Male Extensive bruising Renal impairment, diabetes type 2, 
CHD 
60 2 22 
9 2013 64 Male Extensive bruising Chronic venous insufficiency 77 < 1 214 
10 2016 86 Male Extensive bruising CHD, renal impairment 84 < 1 47 
11 2018 73 Male Extensive bruising CHD, COPD, renal impairment 119 < 1 7 
12 2019 77 Male Extensive bruising, GI 
bleeding, compartment 
syndrome 
Multiple myeloma, hypertension, 
atrial fibrillation, renal impairment 
119 < 1 102 








































































Definition of Outcomes 
FVIII recovery or complete remission, respectively, was defined
as a stable FVIII recovery of higher than 70 IU/dL. Partial remission
was defined as a FVIII recovery of more than 30 IU/dL [49] . Reduc-
tion of inhibitor titer was defined as a titer below 10 BU/mL and/or
a decline of more than 70% [50] . Mortality was defined as overall
mortality or the proportion of patients who died within the given
observation period. 
Statistical Analysis 
For descriptive purposes, numbers and/or proportions and me-
dian and/or range were used as appropriate. Pooled proportions
of patients with FVIII recovery (complete response), reduction of
inhibitor titer and deaths were calculated in relevant subgroups
using the binominal distribution and Freeman-Tukey double arc-
sine transformation [51 , 52] . Heterogeneity was tested using the I 2
statistics, which describes the proportion of total variation due to
between-study heterogeneity. Sensitivity analyses were conducted
in retrospective studies and in studies using different absorbing
agents (Protein A sepharose vs Ig-Therasorb vs Immuno-sorba TR-
350). The Stata 14.1 statistics software package (StataCorp. 2015.
Stata Statistical Software: Release 14.2. College Station, TX, USA:
StataCorp LP) was used for statistical analyses. 
Results 
Characteristics, Treatment, and Outcomes 
Within our institution, 12 patients with acquired hemophilia
have been treated since 2002; detailed patient characteristics are
shown in Table 1 . The median age was 76 years (range 34-86)
and 4 patients were female. The bleeding phenotype was exten-
sive bruising and/ or muscle hematomas in 9 patients, gastroin-
testinal bleeding in 2 patients and extensive bleeding after tooth
extraction in 1 patient. At admission, median aPTT was 72.5 sec-
onds (range 52-130), FVIII activity was below 1 IU/dL in 9 pa-
tients, and median FVIII inhibitor was 20 BU/mL (range 3-214).
Treatment criteria for IA was either (1) failed response to immuno-
suppressive therapy alone, (2) severe bleeding episodes that could
not be controlled, or (3) high inhibitor titer. Clinical and labora-
tory outcomes are reported in Table 2 . Observation period varied
from 22 days to 4 years and the number of IA sessions varied
from 2 to 9. In each session, we treated 2 to 2.5 times the pa-
tients’ plasma volume. Cyclophosphamide was used in addition toPlease cite this article as: M. Esteves Pereira, C. Bocksrucker, J.A. Kreme
Hemophilia: New Observational Data, Systematic Review, and Meta-A
tmrv.2021.01.001 steroids (prednisolone in 10 patients and methylprednisolone in 2
patients) as immunosuppressive treatment in all patients. Other
factor concentrates (recombinant factor VIIa, activated prothrom-
bin complex concentrate, (human) FVIII concentrate), and intra-
venous immunoglobulin G were used in some patients. At day 30,
the median FVIII was 34 IU/dL (range < 0.01-241) and the median
inhibitor titer was 1.1 BU/mL (range 0-326.5). At 3 months, the me-
dian FVIII was 80 IU/dL (range 32-360) and the median inhibitor
titer was 0.15 BU/mL (range 0-2). After 1-year, median FVIII was
147 IU/dL (range 132-162), and the median inhibitor titer was 0
(for only 2 available patients). Bleeding could be stopped in 9 pa-
tients and 3 patients did not respond to the treatment. 
Selection of Studies and Methodological Quality 
Our literature search yielded 498 records ( Figure 1 ). After re-
moval of duplicates, the title and abstract were screened in 4 4 4
records. We selected 52 publications for full-text review of which
42 were excluded because IA was not applied, because of double
publication, or missing data. Adding our own data, we included
eleven studies comprising 118 patients ( Table 3 ). The overall qual-
ity of primary studies according to the adapted NOS was rated as
moderate. The most important limitations were that (1) no control
group was available, and (2) data were collected retrospectively in
all but 1 case [53] . Thus, items 2 and 5 from the adapted NOS
were rated as “unfavorable” in all studies; the ratings of the other
items of NOS are shown in Figure 2 . The study populations were
regarded as “very representative” because all patients were treated
in 3 of 11 studies, and “somewhat representative” in all other stud-
ies. The items “Were patients really treated” and “Were end points
absent at the time of inclusion” were rated as “Yes” in all studies.
For all end points, data were available, but no blinded assessment
was done. Follow up was carried out ≥3 months in 9 of 11 studies,
and the frequency of patients lost to follow-up was below 20% in
all studies. The individual ratings for all studies are shown in the
Supplementary Table S1. 
Systematic Review 
Reports of 106 patients with acquired hemophilia treated with
IA were identified; the observation period varied between 43 days
[37] and 14 years [53] . Details are reported in detail below, patient
characteristics are summarized in Table 3 , treatment details and
outcomes are given in Table 4 . 
In a retrospective analysis, Gjoerstrup et al report about 3 non-
pregnant patients (43, 62, and 75 years of age; 1 female) with ac-r Hovinga et al., Immunoadsorption for the Treatment of Acquired 
nalysis, Transfusion Medicine Reviews, https://doi.org/10.1016/j. 
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Table 2 





IA-sessions a Absorbing agent Co-treatment FVIII recovery b Reduction of 
inhibitor titer c 
Clinical outcome 
Months IU/dL BU/mL 
1 1 2 Protein-A-Sepharose - Cyclophosphamide 75 mg/d 34 (30d) nr Bleeding stopped 
- IVIG 0.5 g/kg/d 
- rFVIIa 6 mg 
- Prednisolone 75 mg/d 
2 1 4 Protein-A-Sepharose - Cyclophosphamide 50 mg/d 2 (30d) 17.6 (30d) Nonresponse 
- Prednisolone 100 mg/d 
- IVIG 0.5 g/kg/d 
3 3 5 Protein-A-Sepharose - IVIG 0.5 g/kg/d 34 (30d) nr Bleeding stopped 
- FVIII concentrate 360 (3m) 
- Prednisolone 50 mg 
- Cyclophosphamide 100 mg/d 
4 3 6 Protein-A-Sepharose - Prednisolone 75 mg/d 25 (30d) 0 (3m) Bleeding stopped 
- Cyclophosphamide 62 (3m) 
- rFVIIa 4.8 mg 
5 1 3 Protein-A-Sepharose - Cyclophosphamide 100 mg/d 241 (30d) 0 (30d) Bleeding stopped 
- Methylprednisolone 125 mg/d 
- Tranexamic acid 500 mg 3x/d 
6 0.8 5 Protein-A-Sepharose - Prednisolone 80 mg/d No recovery No reduction No response 
- rFVIIa 90 μg/kg 
- Cyclophosphamide 100 mg/d 
7 2 7 Protein-A-Sepharose - Cyclophosphamide 100 mg/d 326.5 (30d) < 1 (30d) No response; death 
- IVIG 0.5 g/kg/d 
- Rituximab 375 mg/kg 
- rFVIIa 90 μg/kg 
- Prednisolone 75 mg/d 
8 12 6 Protein-A-Sepharose - Prednisolone 75 mg/d 11 (30d) 2.1 (30d) Bleeding stopped $ 
- Cyclophosphamide 100 mg/d 80 (3m) 0.3 (3m) 
- rFVIIa 90 μg/kg 132 (12m) 0 (12m) 
9 48 4 Protein-A-Sepharose - Cyclophosphamide 100 mg/d 194 (30d) 0.2 (30d) Bleeding stopped 
- IVIG 0.5 g/kg/d 43 (3m) 0.5 (3m) 
- Prednisolone 75 mg/d 162(12m) 0 (12m) 
10 6 5 Protein-A-Sepharose - Prednisolone 100 mg/d 123 (30d) 1.2 (30d) Bleeding stopped; 
- Cyclophosphamide 100 mg/d 32 (3m) 2 (3m) relapse 3 months after 
diagnosis; death 6 
months after diagnosis 
- rFVIIa 90 μg/kg 
11 3 9 Protein-A-Sepharose - Methylprednisolone 125 mg 141 (30d) 0 (30d) Bleeding stopped 
- aPCC 3700 U 150 (3m) 0 (3m) 
- rFVIIa 90 μg/kg 
- Cyclophosphamide 100 mg/d 
- Prednisolone 75 mg/d 
12 5 7 Globaffin - Prednisolone 1 mg/kg/d 48 (30d) 1 (30d) Bleeding stopped 
- Cyclophosphamide 150 mg/d 199 (3m) 0 (3m) 
aFVII, activated factor VII; aPCC, activated prothrombin complex concentrate; IVIG, intravenous immunoglobulin G; nr, not reported. 
a Number of IA sessions. 
b the factor VIII activity is given at 30 days (30d), 3 months (3m), and 12 months (12m) as available. 
c the inhibitor titer in Bethesda units is given at 30 days (30d), 3 months (3m), and 12 months (12m) as available; $, death 1 year after diagnosis independent from 
acquired hemophilia. 
Table 3 
IA treatment of acquired hemophilia: Patient characteristics in primary studies. 
# Author, year No. of 
patients 
Design Age Sex Observation 
period 














[54] Gjörstrup, 1991 3 Retrospective 62 (43-75) 2/1 nr nr nr 63 (36-155) 
[50] Watt,1992 9 Retrospective 58 (24-76) 6/3 3 nr 5 ( < 5-8) 600 (8-1587) 
[55] Jansen, 2001 7 Retrospective 70 (24-77) 5/2 2.1 90 (70-200) < 1 ( < 1-15) 114 (18-540) 
[37] Guillet, 2001 2 Retrospective 29/62 1/1 0.1-1 95-56 4 ( < 1-7) 15 (22-8) 
[56] Mansouri 
Taleghani, 2001 
4 Retrospective 59 (27-67) 2/2 0.7 (0.25-1) Nr nr 100 (3-138) 
[57] Rivard, 2003 5 Retrospective 59 (28-80) 2/3 3 114 (150-122) 1 ( < 1-15) 100 (12-144) 
[39] Brzoska, 2007 9 Retrospective 70 (50-78) 6/3 2 Nr 2 37 (3.61-1085) 
[41] Seibert, 2011 1 Retrospective 73 0/1 nr 89 1 1500 
[53] Zeitler, 2013 65 Prospective 67 (28-89) 27/38 1-14 67 (28-89) < 1 228 (8-3600) 
[63] Bilgin, 2013 1 Retrospective 78 1/0 0.5 157 4 10 
Current Esteves Pereira, 
2021 
12 Retrospective 76 (range 34-86) 8/4 0.4 (0.1-4) 73 (52, 130) < 1 ( < 1-3) 20 (3-214) 
nr, not reported. 
Cohort studies, case series, and case reports were included. 
a before treatment. 
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Fig. 1. Selection process of primary studies. 
Table 4 
IA treatment of acquired hemophilia: Treatment details and results. 
# Author, year Nr. of IA Absorbing 
agent 
Co-treatment FVIII recovery Reduction of 
inhibitor titer 
Death 
median (range) Number of 
patients out of 
all patients 
Number of 
patients out of 
all patients 
Number of 
patients out of 
all patients 




2/3 2/3 0/3 
[50] Watt, 1992 3,5 (2-6) Protein A 
Sepharose 
Various drugs 5/7 7/7 0/9 
[55] Jansen, 2001 7 (4-19) Therasorb-Ig aPCC, steroids, cyclophosphamide 6/7 6/7 0/7 
[37] Guillet, 2001 3.5 (3-4) Protein A 
Sepharose 
rFVIIa, steroids, cyclophosphamide 1/2 2/2 1/2 
[56] Mansouri 
Taleghani, 2001 
3 (1-4) Protein A 
Sepharose 
nr 4/4 4/4 0/4 
[57] Rivard, 2003 5 (4-5) Protein A 
Sepharose 
hFVIII, hFIX, hFXIII, rFVIIa, pFVIII, 
steroids, cyclophosphamide 
4/5 4/5 1/5 
[39] Brzoska, 2007 11 (4-20) Immusorba 
TR-350 
rFVIIa, steroids, cyclophosphamide 7/9 8/9 2/9 
[41] Seibert, 2011 24 Immusorba 
TR-350 
Fresh frozen plasma, IVIG, rFVIIa, 
tranexamic acid, steroids, 
cyclophosphamide 
0/1 0/1 nr 
[53] Zeitler, 2013 16 Therasorb-Ig Steroids, cyclophosphamide, 
azathioprine, vincristine, 
rituximab 
54/65 63/65 6/65 
[63] Bilgin, 2013 5 nr rFVIIa, steroids, cyclophosphamide 1/1 1/1 1/1 
Current Esteves Pereira, 
2021 
5 (2-7) Protein A 
Sepharose 
Steroids, cyclophosphamide, 
hFVIII, rFVIIa, tranexamic acid, 
IVIG, rituximab 
8/10 6/8 2/8 
aPCC, activated prothrombin complex concentrate; hFVIII, human factor VIII; IVIG, intravenous IgG; nr, not reported; PCC, prothrombin complex concentrate; pFVIII, porcine 
factor VIII; rFVIIa, recombinant activated factor VII. 
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Fig. 2. Methodological quality of observational studies according to an adapted 
Newcastle-Ottawa Scale. The proportions of studies are shown; the individual items 
are (1) Are reported patients representative for all treated patients?, (2) Selection 
of the control group, (3) Were patients really treated?, (4) Were end points absent 
at the time of inclusion?, (5) Are exposed and unexposed patients comparable?, 



































































































quired hemophilia [54] . The treatment indication was acute bleed-
ing, and all patients had high inhibitor titers (36, 850, and 1500
BU/mL). Two to 4 cycles of IA using Immunosorba protein A
sepharose were applied in addition to steroids, cyclophosphamide,
intravenous immunoglobulins, and FVIII concentrate. Recovery of
FVIII and a marked reduction of the inhibitor titer was observed in
2 of 3 patients; no deaths occurred. No side effects were reported,
and the observation period was not mentioned. 
Watt et al summarized data of 9 nonpregnant patients with ac-
quired hemophilia (median age 58 years, range 14-76; 3 females),
which were included in an application of an Investigational Device
Exemption (IDE) to the Food and Drug Administration (FDA) [50] .
The median FVIII activity was 5 IU/dL (range < 5-8), and the me-
dian inhibitor titer was 600 BU/mL (range 8-1587); the treatment
indication was severe bleeding. Two to 6 IA cycles using protein A
sepharose were used, and various additional treatments were ap-
plied. Even though the inhibitor’s titer was markedly reduced in
7 of 7 patients (not recorded in 2 patients), FVIII recovery was
achieved only in 5 of 7. The bleeding stopped in all but 1 patient.
No deaths were reported, but the observation period was 4 weeks
only. Adverse events were assessed carefully, and grade I events re-
ported: nausea and vomiting in 11% of the procedures, paresthesia
due to chelation of ionized Ca2 + in 10%, and mild hypotension in
6%. 
In another retrospective analysis, Jansen et al report about 7
patients with acquired hemophilia (median age 58, range 24-76;
2 female), including 1 patient with a pregnancy-associated dis-
ease, and 1 patient with pre-existing rheumatoid disease [55] . The
treatment indication was severe bleeding in 4 cases and high in-
hibitor titer in all other cases (median titer 114 BU/mL, range 18-
540; median FVIII activity < 1 IU/dL, range < 1-15). In addition to
steroids and cyclophosphamide, patients received FVIII, activated
factor VII, activated prothrombin complex concentrate, or fresh
frozen plasma. Four to 19 cycles of IA using Therasorb®-Ig were
applied. Recovery of FVIII and marked reduction of the inhibitor
titer was recorded in 6/7 patients. Remission was not achieved in
an elderly male patient (76 years) with a high inhibitor titer (540
BU/ml). No deaths were reported over an observation period ofPlease cite this article as: M. Esteves Pereira, C. Bocksrucker, J.A. Kreme
Hemophilia: New Observational Data, Systematic Review, and Meta-A
tmrv.2021.01.001 several months (not specified); mild side effects, including nausea
and flushing, was reported in 6% of the cycles. 
Guillet et al retrospectively describes 2 patients [37] : A 29-year-
old male patient with underlying autoimmune disease who ex-
perienced massive abdominal hemorrhage with shock following a
liver biopsy (FVIII < 0.01 IU/mL, inhibitor titer 80 BU/mL), and a
62-year-old female patient with rheumatoid arthritis and massive
retroperitoneal hemorrhage (FVIII = 0.03 IU/mL, inhibitor titer 15
BU/mL). Indication for IA was a treatment-refractory situation in
both cases. Three or 4 IA cycles using protein A Sepharose were
applied in addition to porcine FVIII, activated prothrombin complex
concentrate, and steroids (case 1) or steroids, cyclophosphamide,
and rFVIIa (case 2), respectively. Even though a marked reduc-
tion in the inhibitor titer was observed in both patients, complete
FVIII recovery was observed in 1 patient only (observation period
1 year). One patient died due to septic shock. 
In another retrospective study, Mansouri et al reports about 4
patients followed for an observation period of 2 to 5 years [56] :
a 27-year-old female with pregnancy-associated IA (76 BU/mL), a
63-year-old female (123 BU/mL), a 54-year-old male (138 BU/mL),
and a 67-year-old male (3 BU/mL). Treatment indication was se-
vere bleeding and high inhibitor titer (3 patients). Further patient
characteristics were not given. One to 4 IA cycles using protein
A Sepharose were applied in addition to steroids and cyclophos-
phamide. Recovery of FVIII and reduction of inhibitor titer were
observed, no side effects or death occurred. 
Rivard et al retrospectively report on 1 female patient with
pregnancy-associated acquired hemophilia (28-year-old), a 67-
year-old male patient with concomitant bladder cancer, an 80-
year-old female with cardiopulmonary comorbidities, a 59-year-old
male, and a 59-year-old female [57] . Treatment indication was high
inhibitor titer (median 100 BU/mL, range 12-144), persistent bleed-
ing despite treatment, or serious comorbidities (patient 2). FVIII
was 1 ( < 1-15) IU/dL. Four to 5 IA cycles using protein A Sepharose
were applied in addition to steroids, cyclophosphamide, and var-
ious factor concentrates ( Table 2 ). Recovery of FVIII and marked
reduction of inhibitor titer was observed in 4 of 5 patients. In the
80-year-old female patient, no remission was achieved, and bleed-
ing was ongoing. The patient died after all treatment was stopped
intentionally. A hematoma related to the central line was reported
as a side effect; the median observation period was 3 years. 
Brozska et al conducted a retrospective analysis in 9 nonpreg-
nant patients followed for a median of 2 years [39] . The median
age was 70 years (range 50-78), 3 patients were female. Various
comorbidities were reported (cancer, polyarthritis, pulmonary dis-
ease, diabetes, and bullous pemphigoid. The median FVIII activity
was 2 IU/dL, median inhibitor titer 37 BU/mL (range 3.61-1085).
Treatment indication was persistent bleeding, and high inhibitor
titer in some cases remained however unclear in other cases. Four
to twenty cycles of IA using Immusorba TR-350 (median 11) were
applied in addition to rFVIIa, steroids, and cyclophosphamide. FVIII
recovery was observed in 7 patients, and the reduction of the in-
hibitor titer in 8 patients; 2 patients died because of persistent
bleeding or pneumonia, respectively. No side effects were reported.
The case of a 73-year-old female patient with cerebral bleed-
ing due to acquired hemophilia was reported by Seibert et al [41] .
The FVIII activity was 1 IU/dL, inhibitor titer 1500 BU/mL. Treat-
ment was initiated on day 17 because of persistent bleeding de-
spite steroids, cyclophosphamide, tranexamic acid, rituximab, and
mycophenolic acid. After 14 IA cycles using Immusorba TR-350,
bleedings stopped, FVIII increased to 5% and the inhibitor titer was
23 BU/mL. Further follow-up was not conducted. 
Zeitler et al prospectively developed a treatment protocol and
treated 65 patients with acquired hemophilia, details of which
were reported in various publications [49 , 53 , 58-62] . Most data
were retrieved from the most complete article [53] , but other pub-r Hovinga et al., Immunoadsorption for the Treatment of Acquired 
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Fig. 3. Factor VIII recovery in patients with acquired hemophilia treated with IA (complete remission). The proportions of patients are shown (denoted as estimate, ES). 
A pooled estimate was calculated using a random-effects binominal distribution incorporating the Freeman-Tukey double arcsine transformation; 95% confidence intervals 


























































lications were also used. The median age was 67 years (28-89),
58% of the patients were female. Pregnancy-associated acquired
hemophilia was present in 6 patients, 8 patients suffered from au-
toimmune disorders, and 5 patients had cancer. Treatment indica-
tion was a high inhibitor titer ( > 5 BU/mL), the median inhibitor
titer was 228 BU/mL (range 8-3600), and median FVIII was below
1 IU/dL. The protocol consists of 16 IA cycles using Therasorb-Ig
in addition to prednisolone and cyclophosphamide; azathioprine,
vincristine, rituximab was given in some cases. FVIII recovery was
observed in 54 cases (83%; partial recovery in 5 more patients),
reduction of the inhibitor titer in 63 patients. Six patients died in
an observation period between 1 and 14 years, the cause of which
was assigned to cancer or infection. Serious side effects were not
reported. 
Bilgin et al reported a 78-year-old male patient with chronic
obstructive pulmonary disease who presented with multiple ecchy-
moses and hematomas [63] . FVIII was < 1 IU/dL, and the inhibitor
titer was 44 BU/mL. Indication for IA was failed treatment with
rFVIIa, steroids, and cyclophosphamide, and ongoing bleeding. FVIII
recovery and the reduction of inhibitor titer were achieved after 5
IA cycles; the columns were not reported. Even though bleeding
stopped rapidly, FVIII recovered, and inhibitor titer was 0 BU/mL,
the patient died after 6 months due to pulmonary disease. 
Meta-Analysis 
The pooled proportion of patients with VIII recovery as defined
above (complete remission) was 86% (95% confidence interval [CI]
76%, 94%), the I 2 statistics was 0%. The forest plot is shown in
Figure 3 . The pooled proportion of patients with a reduction of the
inhibitor titer was 95% (95%CI 83%-100%), the I 2 statistics was 32%
( Figure 4 ). The pooled mortality was 7% (95%CI 0%-18%; I 2 = 24%;
Figure 5 ). Sensitivity analyses did not reveal any significant differ-
ences in retrospective studies or in studies using different absorb-Please cite this article as: M. Esteves Pereira, C. Bocksrucker, J.A. Kreme
Hemophilia: New Observational Data, Systematic Review, and Meta-A
tmrv.2021.01.001 ing agents (Protein A Sepharose vs Therasorb-Ig vs Immusorba TR-
350). 
Discussion 
The number of studies investigating IA for the treatment of ac-
quired hemophilia is limited and most of them are retrospective
case series. Additionally, observation period varied between few
days and several years. Many patients were treated because of a
high inhibitor titer, severe bleeding events, or a failed response to
routine treatment with steroids and cyclophosphamide. Recovery
of FVIII and reduction of the inhibitor titer was achieved in the
majority of patients, while the mortality was limited. Factors asso-
ciated with study design, patient population, or treatment details
affecting clinical outcomes were not apparent. 
This is the first systematic review summarizing available liter-
ature on IA for the treatment of acquired hemophilia and pooling
available data. The results extracted from our analysis are better
than in most previous studies conducted without IA. A complete
remission frequency of 73% has been reported in the European
EACH2 registry [16] . In a study conducted in Germany, Austria,
and Switzerland (GTH-AH), a complete remission was observed in
61% of the patients [26] . In a UK-based surveillance study, com-
plete remission occurred in 71% of the patients [25] . In the French
SACHA study, complete remission was reported in 61% of the pa-
tients [24] . Our results are favorable also with regard to mortality
(26% in EACH2, 33% in GTH-AH, 43% in the UK study, and 33% in
SACHA). And it is noteworthy that patients treated with IA are at a
high-risk for bleeding or in a treatment-refractory situation. 
The strength of our investigation is that we conducted a com-
prehensive literature search using a well-designed search strategy
and covering 2 major databases (MEDLINE, EMBASE). In addition,
we applied strict inclusion criteria and 2 investigators searched the
literature and retrieved the data in parallel. Our study has limita-r Hovinga et al., Immunoadsorption for the Treatment of Acquired 
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Fig. 4. Reduction of inhibitor titer in patients with acquired hemophilia treated with IA. The proportions patients are shown (denoted as estimate, ES). Pooled estimate was 
calculated using a random-effects binominal distribution incorporating the Freeman-Tukey double arcsine transformation; 95% confidence intervals were computed using the 
score statistic. 
Fig. 5. Mortality of patients with acquired hemophilia treated with IA. The proportions of patients are shown (denoted as estimate, ES). A pooled estimate was calculated 
using a random-effects binominal distribution incorporating the Freeman-Tukey double arcsine transformation; 95% confidence intervals were computed using the score 
statistic. 
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tions, however, and we cannot fully exclude that this might have
influenced our results. First, the methodological quality was mod-
erate only and no control group was included in any study. As with
other rare diseases, no randomized controlled trials are available
studying the treatment of acquired hemophilia. This makes it im-
possible to accurately assess the actual “added value” over the rest
of the treatment. However, the FVIII recovery rate was high despite
the patients being treated being at high risk for bleeding and in a
treatment-refractory situation. Secondly, we cannot fully exclude a
publication bias resulting from unsuccessful treatments that were
not published. However, most authors mention that the patient co-
hort is complete with regard to all patients treated. Thirdly, pooled
estimates of proportions might be imprecise and even biased if
studies have either 0 or 1 or in case of extreme differences in
the number of participants in case Freeman-Tukey double arcsine
transformation is used [64] . However, we believe that the risk is
low in our study because (1) the differences in study size are much
smaller than in the analysis mentioned above, and (2) the magni-
tude of the effect sizes is comparable among studies if case reports
are excluded. Fourthly, we were not able to conduct a proper sen-
sitivity analysis because primary studies did not provide data on
different cut-offs. Even though we cannot fully conclude that this
might have introduced any bias, we did not have identified appar-
ent sources of variability. Fifthly, the observation periods varied re-
markably, even within studies, and we cannot entirely exclude that
this might have introduced any bias. However, there are currently
no studies available with a better methodology. 
Even though firm evidence is still lacking and the actual “added
value” of IA cannot be adequately assessed, we believe that IA
might be a beneficial adjunctive treatment modality in some pa-
tients with acquired hemophilia. It was associated with a complete
remission in the majority of patients, most of whom are at high
risk of bleeding. Few side effects were reported; most of them
were mild only (nausea and vomiting; paresthesia; and mild hy-
potension). However, a central venous catheter is often used, ex-
posing the patient to a risk of bleeding and infection. Thus, we
believe that adjunctive IA is justified in selected high-risk patients
with acquired hemophilia. The question arises whether IA might
improve clinical outcomes in the long-term. Even though rates
of platelet recovery, reduction of inhibitor titer, and death are at
least comparable to large registries of unselected patients [16] , out-
comes cannot be compared directly because of different observa-
tion periods. This issue must be clarified in future studies directly
comparing different treatment strategies. Although IA is, per se,
an expensive procedure, the often-necessary regular treatment of
this patient group with FVIII bypassing agents is very much higher
and may even be already be justified, if this period can be short-
ened by 1 or 2 days. Indeed, some authors have previously argued
that the expenditure associated with IA is counterbalanced by a re-
duced need for coagulation factors such as rFVIIa or pFVIII [34 , 55] .
IA is only available in a limited number of specialized centers in
Switzerland. The procedure takes about 6 to 8 hours and has to be
done in combination with a regular apheresis machine for plasma
separation. An IA with a nonreusable column is reimbursed with
ca. 1500 CHF per adsorption round. Using an IA with a reusable
column, the reimbursement is ca. 30 0 0 CHF per adsorption round.
At our institution, IA is considered on a case-by-case base rather
than a strict cut-off level. Strong arguments are (1) live-threatening
bleeding complications, (2) inhibitor titers ≥20 BU/mL, or (c) failed
immunosuppressive treatment with corticosteroids and cyclophos-
phamide using an established dose regimen [3] . 
In conclusion, our data suggest that IA might be a beneficial
adjunctive treatment modality in high-risk patients with acquired
hemophilia. Future register data would be expected to add impor-
tant information to the current state of knowledge. 
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